Abstract: Provided herein are magnetically-responsive, photosensitizer based antimicrobial microemulsions and photodynamic nanoplatforms in which a photosensitizer functionally associated with a plurality of superparamagnetic iron oxide nanoparticles are encapsulated. Also provided are methods and processes utilizing the antimicrobial microemulsions and photodynamic nanoplatforms to treat an oral disease, to reduce a microbial population in a pathogenic oral biofilm and to improve the efficacy of a photosensitizer during an antimicrobial photodynamic therapy treatment of an oral disease.

Abstract: Solid-state lithium ion electrolytes of lithium metal nitride based compounds are provided which contain an anionic framework capable of conducting lithium ions. Materials of specific formulae are provided and methods to alter the materials with inclusion of aliovalent ions shown. Lithium batteries containing the composite lithium ion electrolytes are provided. Electrodes containing the lithium metal nitride based composites are also provided.

Abstract: Embodiments of the disclosure concern compositions and methods of use related to particular c-kit+ mesenchymal cells, including cardiac stem cells, obtained from a pediatric or neonatal individual. In specific embodiments, the cells, or conditioned medium or partial or total secretomes thereof, are provided in an effective amount to an individual in need thereof.

Abstract: Provide herein are compounds with a general chemical structure of: Substituents R1 and R2 independently are H, Cl, F, Br, CH3, CF3, SH, —N(C1-3alkyl)2, —NHC(O)C1-3alkyl, or —NHC(O)C5-7cycloalkyl, substituent R3 is H or C1-3 alkyl and R4 is a bridged cycloalkene such as a bridged cyclohexene or a bridge-substituted cyclohexene. The compounds are therapeutics to treat a cancer, such as breast cancer, or metastatic cancers, to inhibit RUNX2 activity, such as protein expression, in a cancer cell and to increase survival of a subject with breast cancer.

Abstract: The present invention provides a method of treating sepsis in a subject, comprising administering to the subject an effective amount of a compound of the formula wherein R1 and R2 may be H, OH, protonated phosphate, a phosphate salt, a sugar phosphonate, or a mono-, di- or poly-saccharide, R3 may be OH or a mono-, di- or poly-saccharide, R4, R5, R6 and R7 may be an alkyl or alkenyl chain of up to 13 carbons (for a chain of 16 carbons), and R8, R9, R10 and R11 may be H, OH, or an alkyl or alkenyl ester of up to 16 carbons, or a salt thereof.

Abstract: A method and apparatus for radiation therapy using functional measurements of branching structures. The method includes determining a location of each voxel of a plurality of voxels in a reference frame of a radiation device. The method further includes obtaining measurements that indicate a tissue type at each voxel. The method further includes determining a subset of the voxels based on an anatomical parameter of a respective branching structure of a set of branching structures indicated by the measurements. The method further includes determining a subset of the voxels that enclose an organ-at-risk (OAR) volume. The method further includes determining a value of a utility measure at each voxel. The method further includes determining a series of beam shapes and intensities which minimize a value of an objective function based on a computed dose delivered to each voxel and the utility measure for that voxel summed over all voxels.

Abstract: Various face discrimination systems may benefit from techniques for providing increased accuracy. For example, certain discriminative face verification systems can benefit from L2-constrained softmax loss. A method can include applying an image of a face as an input to a deep convolutional neural network. The method can also include applying an output of a fully connected layer of the deep convolutional neural network to an L2-normalizing layer. The method can further include determining softmax loss based on an output of the L2-normalizing layer.

Abstract: Disclosed are devices and methods for automated emergency arterial cannulation. The device comprises a hand-held automated emergency arterial sheath placement device having a body with a handle and an actuator, and an arterial sheath placement head at the distal end of the handle body configured for placement against the patient's skin. The arterial sheath placement head includes an arterial sheath insertion device configured to advance an arterial needle, guide wire, and arterial sheath into a patient's artery upon sequential operation of the actuator. The arterial sheath placement head also includes a non-invasive artery locator configured to locate an artery into which the arterial sheath is intended to be placed. The arterial sheath placement head also preferably includes a Doppler gel and antiseptic needle, a local anesthetic needle, and a scalpel, all of which are likewise configured to advance from the upper body portion upon sequential operation of the actuator.

Abstract: The present invention is directed to aqueous solid polymer electrolytes that comprise a lithium salt and battery cells comprising the same. The present invention is also directed to methods of making the electrolytes and methods of using the electrolytes in batteries and other electrochemical technologies.

Abstract: Novel retinamides with unique properties and biological activities, including inhibition of retinoic acid metabolism and modulation of Mnk1/2-eIF4E and androgen receptor (AR) signaling pathways, are synthesized and developed. The novel retinamides are capable of effecting treatment of a variety of dermatological conditions while limiting adverse side effects.

Abstract: Prodrugs of colchicine, de-acetyl colchicine, colcemid, and nocodazole are provided as therapies for the treatment of diseases ameliorated by the inhibition of microtubule polymerization.

Abstract: This invention is a computer-implemented method and system of using a secondary classification algorithm after using a primary source code vulnerability scanning tool to more accurately label true and false vulnerabilities in source code. The method and system use machine learning within a 10% dataset to develop a classifier model algorithm. A selection process identifies the most important features utilized in the algorithm to detect and distinguish the true and false positive findings of the static code analysis results. A personal identifier is used as a critical feature for the classification. The model is validated by experimentation and comparison against thirteen existing classifiers.

Abstract: Technologies for the prevention and/or treatment of nosocomial infections.

Abstract: Metastatic triple negative breast cancer (TNBC) still carries a dismal prognosis with the current treatment paradigms. The effectiveness of drug treatment for many solid tumors such as TNBC is limited by tumor heterogeneity, lack of tumor specificity, off-target toxicities, and transient therapeutic action(s). Strategies that provide tumor-specific, sustained concentrations of drugs to the tumors and tumor receptor-specific binding, while reducing off-target effects are needed to ensure sufficient tumor cell uptake within the primary and metastatic tumor microenvironment. The decreased non-specific adhesivity, receptor-targeted nanoparticle formulations (“DART” nanoparticles) of the invention were assessed for clinical potential in directing biological agents to the cell surface receptor Fn14, which is expressed in many solid cancer types, including TNBC primary tumors and metastatic lesions.

Abstract: The present invention relates to rhomboidal phase bismuth oxide that maintains electric conductivity of at least about 1×10?2 S/cm at temperature of about 500° C. for at least about 100 hours. In particular, the bismuth oxides of the invention have stable conductivity at a temperature range from about 500° C. to about 550° C.

Abstract: The present invention provides a method of lowering blood pressure in a subject, comprising genetically modifying a myosin phosphatase target subunit (Mypt1) gene in a vascular smooth muscle cell of the subject, whereby the genetic modification of Mypt1 results in a deletion or inactivation of exon 24. The invention further provides vectors, host cells, and compositions useful for carrying out the methods of the invention.

Abstract: A monitoring device for a battery pack, which includes a plurality of battery cells, has at least one ultrasound source and at least one ultrasound sensor. The ultrasound source can be configured to generate and direct ultrasound at one or more battery cells of the battery pack. The ultrasound sensor can be configured to detect ultrasound reflected from or transmitted through one or more cells of the battery pack. A battery management unit receives one or more signals from the ultrasound sensor responsive to the detected ultrasound. The battery management unit can be configured to determine a state of the battery pack based at least in part on the detected ultrasound.

Abstract: The present invention provides improved devices for co-culture of cells. The devices include inserts having invertible wells that can be lowered into a well of any standard cell culture plate. A first population of cells can be cultured in the invertible wells of the inserts and a second population of cells can be cultured in the wells of a cell culture plate. Once the first population of cells attach to the invertible wells, the inserts are flipped over and placed into the wells of the cell culture plate to co-culture with the second population of cells.

Abstract: Examples of the present disclosure include the use of a topological system including an array of coupled ring resonators that exhibits topological edge states to generate frequency combs and temporal dissipative Kerr solitons. The topological edge states constitute a travelling-wave super-ring resonator causing generation of at least coherent nested optical frequency combs, and self-formation of nested temporal solitons that are robust against defects in the array at a mode efficiency exceeding 50%.

Abstract: Disclosed are peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a neonatal receptor (FcRn); an influenza HA protein; and a trimerization domain. Disclosed are compositions comprising one or more of the peptides described herein. Disclosed are nucleic acid sequences capable of encoding any one of the peptides described herein. Disclosed are methods for eliciting a protective immune response against influenza comprising administering to a subject an effective amount of a composition comprising a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; an influenza HA protein; and a trimerization domain, wherein the administering is to a mucosal epithelium.